FDA Approves CMV Test for Baby Virus Hunt
Published Date: 5/9/2025
Rule
Summary
The FDA is officially classifying a special test that detects cytomegalovirus (CMV) in newborns as a Class II device, meaning it has special safety rules but is easier to get to patients. This change helps make sure the test is safe and effective while speeding up access to this important tool for babies and families. The new rules took effect on May 9, 2025, and could lower costs and delays for companies making these tests.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 1 costs, 0 mixed.
Newborn CMV Test Moved to Class II
The FDA classified the cytomegalovirus (CMV) nucleic acid detection device for diagnosing congenital CMV in newborns as Class II (special controls). The order is effective May 9, 2025, and the classification was applicable on November 30, 2018. FDA says this classification provides reasonable assurance of safety and will enhance patients' access to the test by reducing regulatory burdens.
Easier Market Path for Test Makers
By classifying this device as Class II via the De Novo process, FDA says the device can serve as a predicate for future devices and that this classification will reduce regulatory burdens and may lower costs and delays for companies making these tests.
Detailed Clinical and Design Study Requirements
The special controls require device sponsors to provide detailed design verification and validation, analytical studies (limit of detection, inclusivity, cross-reactivity, stability), and clinical study documentation that demonstrates sensitivity and specificity. Clinical study subjects must be consistent with the intended use population (infants younger than 21 days of age), results must be compared to FDA-accepted comparator methods, and if positive samples are insufficient sponsors must evaluate additional pre-selected positive samples.
Breastfeeding Timing Requirement for Samples
Labeling must include a statement that breast milk can cause false positive saliva results if samples are collected less than 1 hour after breastfeeding. The labeling must recommend collecting samples a minimum of 1 hour after breastfeeding.
Test Result Interpretation Warnings
Labeling must state that negative CMV test results do not rule out infection and should not be the sole basis for diagnosis or treatment, and that positive results should be interpreted with other clinical and laboratory information.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-08145, Medical Devices; Immunology and Microbiology Devices; Classification of the Microbial Nucleic Acid Storage and Stabilization Device
The FDA is officially putting microbial nucleic acid storage and stabilization devices into class II, meaning they’ll have special safety rules but less red tape. This change helps companies bring these devices to market faster while keeping patients safe. It affects manufacturers and healthcare providers starting May 9, 2025, and aims to boost innovation without extra costs.
Next: 2025-08147, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Breast Milk Macronutrients Test System
The FDA is officially putting the breast milk macronutrients test system into Class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps companies bring these helpful devices to moms and babies faster and safer. The new rules took effect on May 9, 2025, making it easier and quicker to get these tests to market without extra costs.